Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Dow
McKesson
Medtronic
Harvard Business School

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Capivasertib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Capivasertib?

Capivasertib is an investigational drug.

There have been 19 clinical trials for Capivasertib. The most recent clinical trial was a Phase 1 trial, which was initiated on June 25th 2019.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.

There are one hundred and forty-nine US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Capivasertib
TitleSponsorPhase
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid TumoursAstraZenecaPhase 1
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaParexelPhase 2
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaAstraZenecaPhase 2

See all Capivasertib clinical trials

Clinical Trial Summary for Capivasertib

Top disease conditions for Capivasertib
Top clinical trial sponsors for Capivasertib

See all Capivasertib clinical trials

US Patents for Capivasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Capivasertib ⤷  Try it Free Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Try it Free
Capivasertib ⤷  Try it Free Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Try it Free
Capivasertib ⤷  Try it Free Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) ⤷  Try it Free
Capivasertib ⤷  Try it Free Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide AstraZeneca AB (Sodertalje, SE) ⤷  Try it Free
Capivasertib ⤷  Try it Free 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy Oncoceutics, Inc. (Philadelphia, PA) ⤷  Try it Free
Capivasertib ⤷  Try it Free Heterocyclic estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) ⤷  Try it Free
Capivasertib ⤷  Try it Free Protein kinase B inhibitors AstraZeneca AB (Sodertalje, SE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Capivasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Capivasertib Australia AU2015244171 2034-04-11 ⤷  Try it Free
Capivasertib Australia AU2015244179 2034-04-11 ⤷  Try it Free
Capivasertib Canada CA2945128 2034-04-11 ⤷  Try it Free
Capivasertib Canada CA2945129 2034-04-11 ⤷  Try it Free
Capivasertib China CN106414451 2034-04-11 ⤷  Try it Free
Capivasertib China CN106459063 2034-04-11 ⤷  Try it Free
Capivasertib European Patent Office EP3129377 2034-04-11 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Dow
McKesson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.